Method for diagnosing and/or evaluating retinal disease

a retinal disease and retinal disease technology, applied in the field of retinal diseases, can solve the problems of reduced vision, loss of eyesight, and the actual effectiveness of isopropyl unoprostone has not yet been evaluated, and achieve the effect of improving the quality of life and the visual cell (rod cells)

US20120087864A1Inactive Publication Date: 2012-04-12R TECH UENO
0 Cites 7 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
Publication Date
2012-04-12
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

The present application provides a method for diagnosing and / or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and / or evaluating circulatory parameters, retinal function, retina morphology and / or visual relating quality of life (QOL).
Need to check novelty before this filing date? Find Prior Art

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation in part of U.S. application Ser. No. 13 / 084,927 that claims priorities to U.S. Provisional Patent Application No. 61 / 323,338 filed Apr. 12, 2010, U.S. Provisional Patent Application No. 61 / 323,342 filed Apr. 12, 2010, U.S. Provisional Patent Application No. 61 / 326,811 filed Apr. 22, 2010, U.S. Provisional Patent Application No. 61 / 362,945 filed Jul. 9, 2010 and U.S. Provisional Patent Application No. 61 / 408,237 filed Oct. 29, 2010, the contents of each of which are herein incorporated by reference in their entirety.BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] The present invention relates to a method for treating retinal diseases using a fatty acid derivative, and the use of an ophthalmic composition comprising the fatty acid derivative. The present invention also relates to a method for improving a visual cell (rod cells and cone cells) function or vision-related quality of life (QOL)...

Examples

formulation example 1

[0229]The respective components were dissolved in purified water so as to adjust to each w / v % shown below, and the solution was aseptically filtered and then filled into a sterilized low density polyethylene container to obtain an ophthalmic solution (one drop volume: approximately 35 μL).

 0.15%isopropyl unoprostone(UF-021) 1.0%Polyoxyethylene sorbitan monooleate 1.0%Mannitol 1.9%Glycerin 0.05%Sodium edetate0.003%Benzalkonium chloride

formulation example 2

[0230]Using the solution prepared by dissolving the respective components in purified water so as to adjust to each w / v % shown below and aseptically filtrating, a sterile unit dose (one-day disposable type) ophthalmic solution was obtained by a Blow Fill Seal system.

0.18%isopropyl unoprostone0.70%Polyoxyethylene sorbitan monooleate0.30%Polyoxyl 10 oleyl ether 4.7% Mannitol0.01%Sodium edetate

formulation example 3

[0231]Using the solution prepared by dissolving the respective components in purified water so as to adjust to each w / v % shown below and aseptically filtrating, a sterile unit dose (single unit dose type) ophthalmic solution was obtained by a Blow Fill Seal system.

0.24%isopropyl unoprostone0.95%Polyoxyethylene sorbitan monooleate0.42%Polyoxyl 10 oleyl ether4.7%Mannitol0.01%Sodium edetate